Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

New questionnaire accurately measures light exercise among dialysis patients

02 Dec 2019
Long waiting times, cost and inconvenience of haemodialysis are off-putting to many patients.

The new Low Physical Activity Questionnaire (LoPAQ) agrees sufficiently with objective pedometer step counts and is an easier method of assessing physical activity in dialysis patients than other, previously validated questionnaires, a recent study has found.

Researchers enrolled 60 patients (mean age, 58.0±12.7 years; 78.3 percent male) on dialysis for at least 3 months and were given a commercially available pedometer for the objective measurement of physical activity. At the same time, the LoPAQ was administered to them at one dialysis session or clinic visit.

The pedometer-derived average weekly step count was 18,578.5 steps, corresponding to a mean of 2,630.5 steps per day. This meant that most patients could be classified as sedentary (<5,000 steps per day) based on their step count.

On the other hand, most patients (82.8 percent) reported using the LoPAQ that they engaged in some form of walking. Participants consumed a medial of 595 kcal per week, equivalent to 24.3 minutes of movement per day. Taking into consideration other forms of exercise, participants spent a total of 33.6 minutes per day of moderate activity. In contrast, a median of 5 hours per day was spent on sedentary activities.

Researchers found that the obtained energy expenditure value from the LoPAQ was significantly correlated with pedometer step counts (p<0.001). The same was true for the total activity reported on the LoPAQ (p=0.01).

Moreover, the duration of sedentary time determined by the LoPAQ was found to be associated lower muscle mass and higher total body fat. The relationship between LoPAQ findings and objective measurements did not differ according to dialysis modality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.